UTI Equity Fund: Focusing on Stocks with Strong Earnings Quality

Sep 10, 2020

Surging COVID-19 cases and the slow pace of demand revival has added to the worries that worst may not be over for the economy yet. This has lead equity mutual fund investors to wait on the sidelines before redeploying their hard-earned money.

Investors who do not want to take very high risk in the current scenario can invest in multi cap funds that have the flexibility to switch between market capitalisation and sectors based on market conditions and prospects. This flexible mandate can help to control the downside risk during depressing market conditions as well as benefit significantly from the recovery.

Multicap funds are riskier than large cap funds, but less risky than mid-cap funds and small-cap funds. It can be considered as a great investment avenue for long-term investors who aim to tap the growth potential of broader equity markets.

UTI Equity Fund (UEF) is one such prudently managed multi-cap funds that has shown extra ordinary performance in the recent market crash and rewarded investors with superior risk-adjusted returns.

Graph 1: Growth of Rs 10,000 if invested in UTI Equity Fund 5 years ago

Launched way back in May 1992, UTI Equity Fund (UEF) is one of the oldest schemes in the Indian mutual fund industry. The fund remained a mute spectator during the 2016-2017 market rally where it significantly underperformed the benchmark. However, it showed stability during the 2018 mid cap crash. The fund’s recategorisation as a multi-cap fund from its previous large-cap oriented mandate offered it the opportunity to add some good mid cap names at a discounted price. The fund has shown a great breakthrough in its performance and stood strong in the recent market crash. Over the last 5 years, UEF has registered a growth of around 10.8% CAGR as against 9.3% CAGR by its benchmark Nifty 500 – TRI, thus outpacing the benchmark by around 1.5 percentage point.

Graph 1
Data as on September 09, 2020
(Source: ACE MF)


 






Table: UTI Equity Fund's performance vis-a-vis category peers

Scheme Name Corpus (Cr.) 1 Year (%) 2 Year (%) 3 Year (%) 5 Year (%) 7 Year (%) StdDev Sharpe
Parag Parikh Long Term Equity Fund 4,508 21.40 9.63 12.29 13.99 18.13 18.50 0.160
Quant Active Fund 36 24.56 6.31 9.49 12.14 19.99 23.77 0.100
UTI Equity Fund 10,983 13.70 1.99 8.21 9.80 15.00 20.60 0.080
Canara Rob Equity Diver Fund 2,280 13.31 4.63 7.47 10.38 14.10 19.09 0.074
Union Multi Cap Fund 371 10.19 2.32 4.90 7.64 11.44 20.16 0.034
DSP Equity Fund 3,726 6.62 2.41 4.59 9.88 15.83 21.46 0.041
LIC MF Multi Cap Fund 295 0.55 -0.88 3.90 4.79 9.87 20.21 0.019
Kotak Standard Multicap Fund 29,714 2.00 -0.30 3.27 10.03 16.74 21.15 0.022
SBI Magnum Multicap Fund 9,063 -1.07 -1.55 1.94 9.27 16.61 20.79 0.004
ICICI Pru Multicap Fund 5,355 -3.51 -6.06 1.78 6.92 13.87 21.83 0.004
Nifty 500 - TRI 4.58 -1.91 3.19 8.60 12.81 21.90 0.019
Returns are point to point and in %, calculated using Direct Plan - Growth option. Those depicted over 1-Yr are compounded annualised.
Data as on September 09, 2020
(Source: ACE MF)
*Please note, this table only represents the best performing funds based solely on past returns and is NOT a recommendation. Mutual Fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not an indicator for future returns. The percentage returns shown are only for indicative purposes.

In the past, UEF has been found struggling to match the performance of its benchmark and similar category peers. However, the wait seems to be over for the fund. With an absolute return of around 13.7% in the last one year, UEF has managed to generate an alpha of around 9 percentage points over the benchmark Nifty 500 - TRI. The recent outperformance has helped it figure among the top quartile performers and has even scaled up its performance across time periods. On a longer 3-year, 5-year, and 7-year periods the fund has managed to significantly outpace the index and has also fared better than many of its category peers.

In addition to this, UEF has shown a fair level of stability. Its standard deviation of 20.60% signifies that the funds volatility has been lower than the benchmark (21.90%), as well as the category average (21.39%). With superior performance in the recent past, the fund has shown significant improvement in its risk-adjusted return. Its Sharpe Ratio of 0.08 is far more competitive in comparison to its prominent category peers and the benchmark.

Investment strategy of UTI Equity Fund

Classified under Multi Cap Funds category, UEF is mandated to invest minimum 65% of its investment in equity & equity related instruments with exposure across market caps. However, there is no minimum limit or restriction specified for any market cap segment. UEF holds a portfolio spread across market capitalisation, but with predominant allocation of around 65% to large caps and up to 35% in mid and small caps.

The fund endeavours to pick high quality businesses run by seasoned quality managements and has the ability to show strong growth for a long period of time using bottom-up approach. The focus is on businesses operating in secular growth industries that can generate economic value through the cycle, rather than cyclical industries which are highly volatile. Accordingly, the fund looks for stocks of quality companies that can perform across market cycles and mitigate drawdowns during depressing market conditions, and rebound faster based on the strong fundamentals of balance sheets & business models.

Graph 2: Top portfolio holdings in UTI Equity Fund

Graph 2 Graph 2
Holding in (%) as on August 31, 2020
(Source: ACE MF)

As of August 31, 2020, UEF held a well-diversified portfolio of around 57 stocks. The fund held its top exposure in names like Bajaj Finance, HDFC Bank, Kotak Mahindra Bank, L&T Infotech, HDFC Ltd., and Infosys together accounting for around 30% of its assets. TCS, Info Edge (India), Astral Poly Technik, and Avenue Supermarts currently figure among the other top holdings in the fund's portfolio. Most of these names have been prominent candidate in the fund's portfolio for over a year now. Notably, the fund has kept itself away from some of the index heavyweights like Reliance Industries, ICICI Bank, HUL, etc.

Stocks like Divi's Laboratories, Info Edge (India), L&T Infotech, Ipca Laboratories, Jubilant FoodWorks, Dr Lal Pathlabs, Torrent Pharma, PI Industries, Berger Paints, etc. contributed immensely to the fund's gains in the last one year.

Around one-fourth of the fund's portfolio is allocated to stocks in the Banking and Financial sector, followed by Infotech, Pharma, Consumption, and Engineering. These top 5 sectors together account for around 64.5% of its assets.Auto, Retail, Healthcare services, and Auto ancillaries are among the other core sectors in the fund's portfolio.

Suitability

UEF has made a mark in terms of returns over the last couple of years. While the rally in large caps has been conducive for the fund's growth, it has managed downsides well during volatile market conditions. Being sector agnostic, the sector weights in the fund's portfolio have been quite distinct from the index and hence the fund's performance may deviate significantly from the benchmark. Moreover, its substantial exposure to mid and small caps can lead to higher volatility. This makes it suitable for investors with high risk appetite and a long term investment horizon of at least 5 years.

 

Warm Regards,
Divya Grover
Research Analyst

 

Editor's note: The last few years have not been among the best for equity mutual funds. While most funds have underperformed or are struggling to match the returns of the benchmark, there are few funds that have the potential to constantly generate alpha for its investors. And we have identified five such high alpha generating funds, in our latest report 'The Alpha Funds Report 2020'. Do not miss our latest research finding. Get your access to this exclusive report, right here!

Note: This write up is for information purpose and does not constitute any kind of investment advice or a recommendation to Buy / Hold / Sell a fund. Returns mentioned herein are in no way a guarantee or promise of future returns. As an investor, you need to pick the right fund to meet your financial goals. If you are not sure about your risk appetite, do consult your investment consultant/advisor. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully.

Join Now: PersonalFN is now on Telegram. Join FREE Today to get ‘Daily Wealth Letter’ and Exclusive Updates on Mutual Funds

 

DISCLOSURE AS PER SECURITIES AND EXCHANGE BOARD OF INDIA (RESEARCH ANALYSTS) REGULATIONS, 2014

About the Company including business activity

Quantum Information Services Private Limited (QIS) was incorporated on December 19, 1989.

QIS was promoted by Mr Ajit Dayal with an objective of providing value-based information/views on news related to equity markets, the economy in general, sector analysis, budget review and various personal products and investments options available to the Public. It was the first company to start equity research on an institutional level.

'PersonalFN' is a service brand of QIS and was started in the year 1999. In 1999, the Company registered the Domain name www.personalfn.com for providing information on mutual funds and personal financial planning, financial markets in general, etc. and services related to financial planning and research in various financial instruments including mutual funds, insurance and fixed income products to customers. It offers asset allocation and researched investment recommendations through its financial planning services.

Quantum Information Services Private Limited (QIS) is registered as Investment Adviser under SEBI (Investment Adviser) Regulations, 2013 and having Registration No.: INA000000680. In terms of the second proviso to Regulation 3 (1) of SEBI (Research Analysts) Regulations, 2014 the Company is not required to obtain Certificate of registration from SEBI.

Disciplinary history

There are no outstanding litigations against the Company, its subsidiaries and its Directors.

Terms and condition on which its offer research report

For the terms and condition for research report click here.

Details of associates

  1. Money Simplified Services Private Limited;

  2. PersonalFN Insurance Services India Private Limited;

  3. Equitymaster Agora Research Private Limited;

  4. Common Sense Living Private Limited;

  5. Quantum Advisors Private Limited;

  6. Quantum Asset Management Company Private Limited;

  7. HelpYourNGO.com India Private Limited;

  8. HelpYourNGO Foundation;

  9. Natural Streets for Performing Arts Foundation;

  10. Primary Real Estate Advisors Private Limited;

  11. HYNGO India Private Limited;

  12. Suresh Lulla;

  13. I V Subramaniam.

Disclosure with regard to ownership and material conflicts of interest
  1. ‘subject company’ is a scheme on which a buy/sell/hold view or target price is given/changed in this Research Report;

  2. Neither QIS, it's Associates, Research Analyst or his/her relative have any financial interest in the subject Company;

  3. Neither QIS, it's Associates, Research Analyst or his/her relative have actual/beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report;

  4. Neither QIS, it's Associates, Research Analyst or his/her relative has any other material conflict of interest at the time of publication of the research report except that QIS (PersonalFN) is, as per SEBI (Mutual Funds) Regulations 1996, an associate / group Company of Quantum Asset Management Company Private Limited and Trustees and Sponsor of Quantum Mutual Fund (QMF) and to that extent there may be conflict of interest while recommending any schemes of QMF. However, any such recommendation or reference made is based on the standard evaluation and selection process, which applies uniformly for all Mutual Fund Schemes. The payment of commission (upfront / annualized & trail), if any, for any Schemes by QMF to QIS (PersonalFN) is also at arm's length and as per prevailing market practices.

Disclosure with regard to receipt of Compensation
 
  1. Neither QIS nor it's Associates have received any compensation from the subject Company in the past twelve months;

  2. Neither QIS nor it's Associates have managed or co-managed public offering of securities for the subject Company;

  3. Neither QIS nor it's Associates have received any compensation for investment banking or merchant banking or brokerage services from the subject Company;

  4. Neither QIS nor it's Associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

  5. Neither QIS nor it's Associates have received any compensation or other benefits from the subject Company or third party in connection with the research report

General disclosure
  1. The Research Analyst has not served as an officer, director or employee of the subject Company.

  2. QIS or the Research Analyst has not been engaged in market making activity for the subject Company.

Click here to read PersonalFN's Mutual Fund Rating Methodology

Subject Company means Mutual Fund Schemes

Quantum Information Services Private Limited CIN: U65990MH1989PTC054667 Regd. Office: 103, Regent Chambers, 1st Floor, Nariman Point, Mumbai - 400 021 Corp. Office: 103, Regent Chambers, 1st Floor, Nariman Point, Mumbai - 400 021.

Email:info@personalfn.com Website: www.personalfn.com Tel.: 022 61361200 Fax.: 022 61361222 SEBI-registered Investment Adviser. Registration No. INA000000680, SEBI (Investment Advisers) Regulation, 2013




Add Comments